Neoadjuvant chemotherapy with Epirubicin / Cyclophosphamid high dose in locally advanced breast cancer (T2-T4/NO-N2/MO)

R. V. Dresel; Dresel R. V.; K. Feltmann; Feltmann K.; A. H. Tulusan; Tulusan A. H.

doi:10.17816/JOWD101355

Neoadjuvant chemotherapy with Epirubicin / Cyclophosphamid high dose in locally advanced breast cancer (T2-T4/NO-N2/MO)

Authors: Dresel R.V.¹, Feltmann K.¹, Tulusan A.H.¹
Affiliations:
1. Klinikum Bayreuth
Issue: Vol 48, No 5S (1999)
Pages: 128-128
Section: Articles
URL: https://journals.rcsi.science/jowd/article/view/101355
DOI: https://doi.org/10.17816/JOWD101355
ID: 101355

Cite item

Full Text

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Objective: The timing of chemotherapy (CHT) in relation to surgery has recently been the subject of intensive investigations. The response of the primary tumor is a reliable prognostic factor and can in addition be regarded as an “in vivo” chemosensitivity test Is it possible to achieve a higher rate of breast conserving therapy (UCT) on locally advanced breast cancer by neoadjuvant treatment? The efficiency on the primary tumor and on the lymphatic nodes will be presented.